---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-290707"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:18:35.712300+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# IN8bio appoints Dr. Corinne Epperly to Board, adopts amended bylaws

## Summary
- Board expanded to 8 directors; Dr. Epperly appointed as Class II director effective Dec 6, 2023, term through 2026 annual meeting.
- Dr. Epperly to serve on Compensation and Science & Technology Committees; former COO of Cargo Therapeutics and SVP at Iovance.
- Bylaws amended to comply with universal proxy rules (Rule 14a-19), enhance stockholder nominee disclosures, and adopt DGCL updates.
- Non-employee director compensation policy updated Dec 5, 2023: annual cash retainer $40k, initial option grant 54,800 shares, annual grant 27,400 shares.

## SEC filing metadata
- accession: 0001193125-23-290707
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/0001193125-23-290707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/d634027d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-290707
- JSON: https://secwatch.observer/filing/0001193125-23-290707.json
- Plain text: https://secwatch.observer/filing/0001193125-23-290707.txt

## Key facts
- Executive change
  Corinne Epperly was appointed as Class II Director at IN8BIO, INC..
  - Action: appointed
  - Role: Class II Director
  source text: appointed Corinne Epperly, M.D., as a Class II director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/0001193125-23-290707-index.htm
- Governance Changes
  IN8BIO, INC.: Board approved and adopted Second Amended and Restated Bylaws with changes addressing universal proxy rules, advance notice requirements, and other updates (effective 2023-12-06).
  - Change: bylaw amendment
  - Effective: 2023-12-06
  source text: On December 6, 2023, the Board approved and adopted the Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), which became effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000119312523290707/0001193125-23-290707-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.